Literature DB >> 19428247

Multiple catalytic aldolase antibodies suitable for chemical programming.

Rajib Kumar Goswami1, Zheng-Zheng Huang, Jane S Forsyth, Brunhilde Felding-Habermann, Subhash C Sinha.   

Abstract

Chemical programming of nine murine antibodies with catalytic aldolase activity was examined using compounds, equipped with diketone or pro-vinyl ketone linkers that inhibit integrin adhesion receptor functions. The results showed that most Abs were programmed using the diketone compounds in a manner similar to previously reported catalytic antibody 38C2. On the other hand, only those antibodies, which catalyzed the retro aldol reaction of the pro-vinyl ketone linkers efficiently, were programmed. Conjugated to integrin targeting compounds, at least three new antibodies, including 84G3, 85H6, and 90G8, exhibited high specific binding to human tumor cells expressing integrin alpha(v)beta(3.).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428247      PMCID: PMC2923540          DOI: 10.1016/j.bmcl.2009.04.041

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

1.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

2.  Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies.

Authors:  Venkata R Doppalapudi; Nancy Tryder; Lingna Li; Teresa Aja; David Griffith; Francesca-Fang Liao; Giovanni Roxas; Mysore P Ramprasad; Curt Bradshaw; Carlos F Barbas
Journal:  Bioorg Med Chem Lett       Date:  2006-10-07       Impact factor: 2.823

3.  Immune versus natural selection: antibody aldolases with enzymic rates but broader scope.

Authors:  C F Barbas; A Heine; G Zhong; T Hoffmann; S Gramatikova; R Björnestedt; B List; J Anderson; E A Stura; I A Wilson; R A Lerner
Journal:  Science       Date:  1997-12-19       Impact factor: 47.728

4.  Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.

Authors:  Mikhail Popkov; Christoph Rader; Beatriz Gonzalez; Subhash C Sinha; Carlos F Barbas
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

5.  Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.

Authors:  Subhash C Sinha; Sanjib Das; Lian-Sheng Li; Richard A Lerner; Carlos F Barbas
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

6.  Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.

Authors:  Lian-Sheng Li; Christoph Rader; Masayuki Matsushita; Sanjib Das; Carlos F Barbas; Richard A Lerner; Subhash C Sinha
Journal:  J Med Chem       Date:  2004-11-04       Impact factor: 7.446

7.  Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis.

Authors:  Brunhilde Felding-Habermann; Richard A Lerner; Antonietta Lillo; Shufei Zhuang; Martin R Weber; Sandra Arrues; Changshou Gao; Shenlan Mao; Alan Saven; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

8.  Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task.

Authors:  A Karlstrom; G Zhong; C Rader; N A Larsen; A Heine; R Fuller; B List; F Tanaka; I A Wilson; C F Barbas; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

9.  Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells.

Authors:  Melanie Rolli; Emilia Fransvea; Jan Pilch; Alan Saven; Brunhilde Felding-Habermann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-21       Impact factor: 11.205

10.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity.

Authors:  B Felding-Habermann; B M Mueller; C A Romerdahl; D A Cheresh
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

View more
  8 in total

Review 1.  Chemoenzymatic methods for site-specific protein modification.

Authors:  David Rabuka
Journal:  Curr Opin Chem Biol       Date:  2010-10-26       Impact factor: 8.822

Review 2.  Chemically programmed antibodies.

Authors:  Christoph Rader
Journal:  Trends Biotechnol       Date:  2014-03-11       Impact factor: 19.536

3.  Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.

Authors:  Yuan Liu; Rajib K Goswami; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2015-06-09       Impact factor: 4.939

4.  The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.

Authors:  Krishna Mohan Bajjuri; Yuan Liu; Cheng Liu; Subhash C Sinha
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

5.  Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro.

Authors:  Rajib K Goswami; Krishna M Bajjuri; Jane S Forsyth; Sanjib Das; Wolf Hassenpflug; Zheng-Zheng Huang; Richard A Lerner; Brunhilde Felding-Habermann; Subhash C Sinha
Journal:  Bioconjug Chem       Date:  2011-08-01       Impact factor: 4.774

6.  Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin.

Authors:  Rajib K Goswami; Yuan Liu; Cheng Liu; Richard A Lerner; Subhash C Sinha
Journal:  Mol Pharm       Date:  2012-11-14       Impact factor: 4.939

Review 7.  Catalytic Antibodies: Design, Expression, and Their Applications in Medicine.

Authors:  Daqun Zhao; Jie Chen; Xiaoyue Hu; Shujun Zhang
Journal:  Appl Biochem Biotechnol       Date:  2022-10-12       Impact factor: 3.094

8.  Crystal structure of two anti-porphyrin antibodies with peroxidase activity.

Authors:  Victor Muñoz Robles; Jean-Didier Maréchal; Amel Bahloul; Marie-Agnès Sari; Jean-Pierre Mahy; Béatrice Golinelli-Pimpaneau
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.